XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:            
Research and development $ 8,262,167   $ 4,033,963   $ 16,048,223 $ 6,183,604
General and administrative 1,497,533   1,938,447   3,681,193 5,042,518
Total operating expenses 9,759,700   5,972,410   19,729,416 11,226,122
Operating loss (9,759,700)   (5,972,410)   (19,729,416) (11,226,122)
Other income:            
Interest income 222,578   36,024   455,113 55,673
Total other income 222,578   36,024   455,113 55,673
Loss before income taxes (9,537,122)   (5,936,386)   (19,274,303) (11,170,449)
Income tax expense (benefit) 0   0   0 0
Net loss $ (9,537,122) $ (9,737,181) $ (5,936,386) $ (5,234,063) $ (19,274,303) $ (11,170,449)
Basic loss per common share $ (1.07)   $ (0.73)   $ (2.25) $ (1.37)
Diluted loss per common share $ (1.07)   $ (0.73)   $ (2.25) $ (1.37)
Weighted average number of common shares outstanding, basic 8,951,309   8,163,923   8,575,239 8,160,702
Weighted average number of common shares outstanding, diluted 8,951,309   8,163,923   8,575,239 8,160,702
As Reported            
Operating expenses:            
Research and development     $ 6,815,708     $ 9,625,499
General and administrative     1,938,447     5,042,518
Total operating expenses     8,754,155     14,668,017
Operating loss     (8,754,155)     (14,668,017)
Other income:            
Interest income     36,024     55,673
Total other income     36,024     55,673
Loss before income taxes     (8,718,131)     (14,612,344)
Net loss     $ (8,718,131)     $ (14,612,344)
Basic loss per common share     $ (1.07)     $ (1.79)
Diluted loss per common share     $ (1.07)     $ (1.79)
Weighted average number of common shares outstanding, basic     8,163,923     8,160,702
Weighted average number of common shares outstanding, diluted     8,163,923     8,160,702
Restatement Impacts            
Operating expenses:            
Research and development     $ (2,781,745)     $ (3,441,895)
Total operating expenses     (2,781,745)     (3,441,895)
Operating loss     2,781,745     3,441,895
Other income:            
Loss before income taxes     2,781,745     3,441,895
Net loss     $ 2,781,745     $ 3,441,895